| Parent Drug Name | Name of Impurity | Catalogue No. | |
|---|---|---|---|
| Atosiban | Atosiban Inhouse Impurity B | VE008049 | View CAS 960411-86-3 |
Atosiban Impurities
| Parent Drug Name | Name of Impurity | Catalogue No. | |
|---|---|---|---|
| Atosiban | Atosiban Inhouse Impurity B | VE008049 | View CAS 960411-86-3 |
[rfq_list]
| Catalogue No. | VE008049 |
| CAS No. | 960411-86-3 |
| Molecular Formula | C43H69N11O12S2 |
| Molecular Weight | 996.2 g/mol |
| Parent drug | Atosiban |
| IUPAC Name | (2S)-N1-((2R)-1-((2S)-2-((5-amino-1-((2-amino-2-oxoethyl)amino)-1-oxopentan-2-yl)carbamoyl)pyrrolidin-1-yl)-3-mercapto-1-oxopropan-2-yl)-2-((2S, 3R)-2-((2S, 3S)-2-((R)-3-(4-ethoxyphenyl)-2-(3-mercaptopropanamido)propanamido)-3-methylpentanamido)-3-hydroxybutanamido)succinamide |
| Synonyms | N/A |
| References | Buddhabunyakan, Nattapong, et al. “Effects of Atosiban on Uterine Peristalsis Following Frozen Embryo Transfer: A Randomized Controlled Trial.” European Journal of Obstetrics & Gynecology and Reproductive Biology, vol. 265, Oct. 2021, pp. 96–101, https://doi.org/10.1016/j.ejogrb.2021.08.017. |
| Status | In-stock |
| ListName | Atosiban Inhouse Impurity B |
| Exclusively Supplied by Veeprho | Exclusively Supplied by Veeprho |
"*" indicates required fields
